Alessandro Crevani has been the General Manager of General Medicine at Sanofi Italy and Malta since 2021.

Born in Pavia in September 1973, he graduated in Pharmacy with a focus on Oncology and Hospital Pharmacy studies from the University of Pavia.

With a career spanning over two decades, Alessandro has demonstrated exceptional skills in managing and developing corporate strategies, marketing strategies, market access, sales, medical affairs, and excelling in product launches at both national and global levels in the fields of oncology, immunology, hematology, urology, cardiovascular, and metabolic disorders.

Throughout his extensive career, Alessandro has held various roles of increasing responsibility at national and international levels in leading global biopharmaceutical companies, including Schering Plough, Sanofi, and Sanofi Genzyme. His dedication and expertise have led him to significant roles within different departments of Sanofi, where he has made substantial contributions to the access and launch of major innovative biologic therapies in Italy.

Alessandro is passionate about healthcare modernization, digital health, artificial intelligence, and all innovations that impact public health. He firmly believes in the social value of the pharmaceutical industry and its employees in creating a positive impact on the community. His leadership has been pivotal in the creation and development of Sanofi's Immunology Franchise, positioning the company as a leader in the sector.

Outside of work, Alessandro enjoys running, cycling, and off-road competitions. He is fluent in English and French, in addition to his native Italian.

• Alessandro is Co-founder and Chief Executive Officer of Axxam S.p.A. He has around 30 years experience in pharma and biotech.

• Alessandro graduated in Biology from the University of Pavia, as a member of the Ghislieri College. He started his career in 1982 as a Research Scientist at the Biotechnology Department of Farmitalia Carlo Erba in Milan, and later was a researcher at the Sir William Dunn School of Pathology at Oxford University (UK). From 1986 through 1989 he served as Head of the Biotechnology Department at the Istituto Sieroterapico Milanese (Milan). During the ‘90s he founded and served as Chief Executive Officer of Primm S.r.l. and later also Director of Technology Transfer at San Raffaele Biomedical Science Park in Milan.

• He is Managing Director at IMAX Discovery GmbH and a member of the Board of Directors of Externautics SpA.

• Since 2003 he has been the Vice-President and in May 2010 was appointed President of Federchimica/Assobiotec, the Italian association for the development of the biotech industry and member of EuropaBio. As of October 2013 he is also member of the Chairmanship Committee of Federchimica with proxy to the new Technology Companies.

• He is author of around 50 scientific publications and inventor of numerous national and international patents.

Since joining Panakes Partners in 2021, Andrea is supporting the venture capital team across deal sourcing, due diligence, and strategic investment in new therapeutics. His work includes in-depth technology, market, and competitive analysis, as well as a focus on assessing unmet medical needs.

Andrea brings experience in pharmacology and drug development, both in preclinical and clinical research, plus expertise in nanotechnology design and development refined during his postdoctoral fellowship at the Houston Methodist Research Institute.

Prior to Panakes, he served as a project manager at BiovelocITA, a leading biotech accelerator supported by Sofinnova Partners, where he focused on seed funding groundbreaking innovations developed by Italian scientists.

Education

MD, University of Milan (Doctor of Medicine)

Fellowship in Clinical Pharmacology and Toxicology, University of Mila

Politecnico Torino
Venture Capital Start-ups Business Strategy
Senior Advisor on investments in Biotechnology

KONTRON INSTRUMENTS CEO(Zurich-Boston)
OLYMPUS MEDICAL SYSTEMS EUROPE (HAMBURG) CEO
OLYMPUS SYSTEM ITALIA(Milano) CEO
IAG (Italian Angels for Growth) CHAIRMAN June 2015 - June 2021
BELLCO S.r.l Mirandola Presidente Consiglio di Amministrazione
(Fondo CHARME- Montezemolo&Partners )

Past Chairman IAG ITALIAN ANGELS FOR GROWTH
RESALIS THERAPEUTICS Board of Directors
CELLPY Board of Directors

University of Oxford Technology Transfer Angels Network

Catello Somma is a Partner at Seroba. He has a background in venture capital and clinical development, with a focus on the biotechnology and medical device industries.

Catello graduated in 2007 summa cum laude from the University of Naples Federico II and in 2014 completed an MBA at POLIMI Graduate School of Management.

Prior to joining the firm in 2024, Catello was at TVM Capital (Munich), involved across different strategies for both biotech and medtech. Before starting a career in venture capital, Catello co-founded a Boston VC-baked biotech start-up (exited), developing therapeutics for oncology and autoimmune diseases. He started his career in 2009 working for different CROs and biotech companies between Italy and Switzerland.

• Claudio Rumazza is a Venture Capital investor, Partner at Innogest. He focuses on healthcare investments and in particular on medical devices, diagnostics and digital health.

• Claudio currently serves on the Board or is involved as a Board observer in Erydel SpA, Igea SpA, D-Eye Srl, Atricath Srl Beintoo SpA, Angiodroid Srl, Pi-Cardia Ltd. and Newronika Srl.

• Before joining Innogest, Claudio was the CFO of Finn-Power Group, head of Financial Planning and Control at Prima Industrie Group and before that he was a consultant with Deloitte Financial Advisory.

• Claudio has a bachelor degree in business administration from University of Torino.

Danilo is a serial entrepreneur and investor in the Health Care and Biotech space with over 30 years of experience.
Founder of several start-ups in multiple geographies with a track record of successful exits.
Chairman and Founder at Nemysis Ltd, an Irish Biotech company
Director at One-Bio in California
Independent Member of the Health Care Investment Committee at Seventure, France
Danilo has served as Senior Executive in Pharma companies in Italy, USA, France, Germany, Ireland, Switzerland, Colombia and the UK
Considerable experience in the “grey area” between food and pharma with a thorough understanding of the Regulatory environment.

Daria currently works as Of Counsel at the law firm BonelliErede, within the Healthcare & Life Sciences Focus Team. She advises leading domestic and foreign companies in the healthcare sector on complex regulatory and contractual topics related to pharmaceuticals, medical devices, food supplements.

Until 2023, she was Group General Counsel at the multinational pharmaceutical group Recordati. Having led for more than 20 years the legal department, she developed a solid experience in complex M&A/licensing transactions and regulatory topics, as well as in corporate governance of listed companies.

Before joining Recordati, she worked as senior legal counsel for a major European player in the toy industry.

She started her carrier in private practice in 1995, at Ernst & Young Legal department in Milan, advising primary domestic and international clients on a broad range of commercial law and company law matters.

She graduated in law at Universita’ Cattolica del Sacro Cuore, Milan, with the highest mark (110/110).
She is admitted to Milan Bar.
She has recently gained a certification in Business Sustainability Management from Cambridge University (Cambridge Institute for Sustainability Leadership)

• Elena is President President of Zambon S.p.A., Vice President of ZaCh (Zambon Chemicals) and member of the board of Zambon Company S.p.A., holding of the Group.

• In June 2014 she has been nominated Cavaliere del Lavoro and has received the award “Imprenditore Olivettiano 2010” and “Marisa Belisario 2010”.

• She is also President of Secofind, member of the Board of Director and the strategic Committee of Italcementi S.p.A. Member of the Board of Fondo Strategico Italiano and of IIT (Istituto Italiano di Tecnologia), and recently appointed member of the Board of Unicredit bank.
• Elena holds a bachelor degree in Business Administration at the University Bocconi in Milan. From 1989 to 1994 worked in Citibank.

• Furthermore, Elena is President of AIDAF, the Italian Association of Family Businesses and Vicepresident (and member of the Executive Committee) of Aspen Institute Italia.

• She is President of Zoé Foundation, and Zambon Open Education.

• Fabrizio is the founder and CEO of Valere, an independent financial advisory house focused on healthcare (www.valereadvisory.com)
• He has 25+ years’ international experience in Corporate Finance, with main focus on M&A, coupled with a deep knowledge of Equity Capital Markets, Private Equity, Debt Advisory, Turnaround, Valuation and Business Modeling
• Fabrizio has a wealth of international transaction experience, having worked on over 100 transactions (mostly cross-border) worth in excess of €24bn
• In the last ten years he has served as advisor on more than 30 Pharma / Healthcare corporate finance projects for Private Equity funds and corporate clients
• In addition, he has extensive management experience as a key contributor in the start-up of four corporate finance teams in three different organizations
• Before founding Valere, Fabrizio used to run the Italian Life Sciences practice at EY (which he started up) from 2015 to 2021
• Before joining EY in 2012, Fabrizio co-founded and developed for four years DVR Capital, a successful start-up independent merchant bank (2008-2012); prior to that, he has worked for ten years at the Investment Banking Division of Salomon Smith Barney / Citi in London, Sydney and Milan (1998-2008)
• Graduated with Honors in Business Law in 1998 at the Bocconi University in Milan, Fabrizio is a native speaker of Italian, is fluent in English and French and has a working knowledge of Spanish

• Federica is Business Development, Scientific Liaison and Drug Safety Director at Rottapharm Biotech, where she is responsible for negotiations, alliances, and licensing activities. In her role as Scientific Liaison, she cultivates relationships with academic researchers and key opinion leaders. Given her long-standing experience in Pharmacovigilance, she is also responsible for all Drug Safety activities in Rottapharm Biotech’s Clinical Trials.
• Before joining Rottapharm, she developed her career at Du Pont Pharma, Helsinn Healthcare, and at IBSA where she served as European Qualified Person responsible for Pharmacovigilance.
• Federica holds a Pharmacy degree from the University of Florence and a Master degree in International Health Care Management, Economies and Policy from the SDA Bocconi School of Management in Milan.
• Federica is a lecturer at the University of Milano-Bicocca, School of Medicine, where she teaches in a Postgraduate Master in Pharmaceutical Medicine.

• Pierfrancesco is CEO of Ricerchimica S.r.l. a consulting company focused on M&A and transaction services in Lifescience. He has over 25-year experience in Pharmaceuticals at European level with particular expertise in the Italian and Spanish market, where Ricerchimica was present, in Barcelona, with their own offices for over 5 years.
• Pierfrancesco has a wide experience in transaction, having worked on over 100 transactions of pharmaceutical assets (companies, manufacturing sites, products, patents, etcc.)
• Since 2015 Pierfrancesco is Senior Advisor in Life Sciences Corporate Finance department at EY S.p.A.

Over the past decade, Gabriele has played a key role in advancing Italy’s life science sector, founding and leading innovative medtech (KLISBio) and biopharma (CaSRevolution) companies. His efforts extend to fostering acceleration programs in partnership with esteemed institutions like Z-Cube and Fondazione Golinelli.

Previously, Gabriele served as Vice President at Credit Suisse Group, overseeing multi-billion euro portfolios for institutional and private clients, with a particular focus on macroeconomic investment strategies.

He is the author of “Capitali di Ventura” and “Future Health” (both published by EGEA) and is also an avid musician.

Education

MBA, INSEAD
MSc, International Economics & Finance
BA, Communications Science

• Gabriele is Vice President at Plexus Ventures, global corporate and business development boutique for life science companies.
• Gabriele supports companies worldwide by providing strategic advice and seeking partners to build their businesses. He advised on several M&A, asset divestments and licensing transactions. In addition to pharma and biotech, Gabriele invests his time and energy in adjacent and innovative spaces, such as medical devices, diagnostics and digital health.
• Prior to joining Plexus, Gabriele worked at Novartis Oncology Region Europe, where he focused on Market Access and Commercial Excellence in 38 countries.
• Gabriele holds a BSc in Business Administration and a MSc in Corporate Finance from Bocconi University in Milan. He is fluent in English and Spanish.

Giovanni Mambrini has served as Quince Therapeutics (Nasdaq: QNCX) Chief Technology Officer since October 2023 and Board Member of Quince’s Italian branch. To this role, he brings more than 25 years of medical device technology experience with cross-functional expertise in bringing complex programs to market, including  experience securing regulatory approval for several innovative products.
Previously, Mambrini served as Chief Operating Officer of EryDel S.p.A. prior to its acquisition by Quince in October 2023. As a co-founder of EryDel in 2008, he has played an integral role in the development of the company’s autologous  intracellular drug encapsulation technology, in addition to serving in a number of
leadership roles, including as Head of Medical Devices and as General Manager for EryDel during the company’s formative years.
Prior to EryDel, Mambrini served in various roles for multinational medical device technology companies with robust development experience across a number of products for blood processing, cardiac surgery, anesthesia, intensive care, combination products, as well as advanced therapies.
Mambrini served as Manager of R&D at Covidien, as Scientific Affair Manager at Dideco, and as Leader of Biocompatibility & Biosensors for the Centre for Innovation and Technological Excellence at Sorin Group Italia, currently LivaNova.
He holds a MSc in Pharmaceutical Technologies and Chemistry from the University of Bologna, in addition to completing a specialized laboratory research program in Biotechnology.

Founder of BluPhytal, a company which, trough its Rare Insight Consulting division, supports healthcare companies to develop their presence in the Orphan Disease arena.

Co-founder of BlueDil International, wich serves as virtual affiliate for Pharma Companies in Europe, providing a cost-effective approach establishing and expanding business in the market of rare disease orphan drugs across Europe and beyond.

From 2016 to 2019 Leonardo has served as Head of Global Rare Diseases Franchise at Chiesi, managing the Strategic Marketing process and supporting Business Development activities.

From 2008 to 2015 Leonardo has created and developed the Italian affiliate of Swedish Orphan Biovitrum (SOBI), managing also Greece and Malta territories. In this role Leonardo has represented SOBI into Assobiotec (Italian Association for the Development of Biotechnologies) becoming member of the directive board.

Previously has spent 20 years in pharma business in positions with increasing responsibility in operational and strategic marketing, mainly in rare or severe diseases.

• Leopoldo is an independent strategic advisor in the Life Science sector.

• In this capacity he has advised various companies on Merger and Acquisitions, out-licensing deals and financing strategy, including advising Nogra Pharma in the largest ever out licensing to Celgene for a compound in development.

• Prior to becoming an independent advisor he was a Senior Managing Director and Head of European, India and MENA Healthcare Investment Banking at Credit Suisse and the Head of the Ultra High Net Worth group from 2007 to 2012.

• From 1994 to 2007, he held various positions at J.P. Morgan, including Head of Healthcare Investment Banking as a Managing Director.

• He servesas a member of the board of directors of Nogra Pharma, Summit Therapeutics, Advanced Accelerator Applications and Qardio. He is also a trustee of Barts and the London Charity, the NHS largest Trust and a founder of the cultural initiative 5×15 Italy.

• Leopoldo received bachelor’s degree in business administration from the Università Commerciale Luigi Bocconi in Milan, Italy.

• Luigi is Axxam’s Chief Financial Officer since 2005. He got his Degree in Electronic Engineering with specialization in management and information systems at the Politecnico di Milano.

• He has spent the first period of his professional career at Biopolo S.c.a.r.l., a technology transfer consulting firm based in Milano, having the opportunity to successfully managed the start up of several strategic and corporate development projects for a number of companies in the biopharmaceutical industry.

• In 2002, Luigi joined Bioxell S.p.A. as Finance Director.

• He is also founder and CEO of Biocity Services, a small service and consulting company located at the OpenZone Science Park in Bresso.

• Luigi has extensive experience in project management and a broad knowledge of finance, accounting and tax principles, regulations and financial control.

• Marco is co-founder of the Swiss based investment firm Continental Investment Partners, of which is one of the two Managing Partners.

• Marco has a 15 years significant transaction track-record as a Global Partner at the Private Equity house 3i Group, with significant results in the management of investments in both private (Giochi Preziosi, Coelsanus Preserves, Vis Pharmaceuticals, Newron) and listed companies (Biosearch Italy, Datamat, Novuspharma).

• In 2010 he became the Head of the Private Equity at Swiss family office Leponte SA and during 2012 he led the public to private takeover of Corin Group plc, an orthopaedic implants company then listed in London.

• Serena holds a P.h.D degree in Molecular/Cellular Biology and is a passionate scientist with over 30 years of experience.
• Owner of B&F BioConsulting company.
• Staff scientist at the biotechnology unit at Dibit-HSR for 13 years.
• Her research activities have been devoted to understanding basic cellular mechanisms in plant and human cell biology using also targeted recombinant plant toxins in applied Experimental Oncology, as documented by more than 40 articles published in leading international scientific journals.
• She led as PI & Coordinator a 5-year collaborative research study “Recombinant Immunotoxin Cooperation Group” (RICG) supported by “Leukaemiabusters”, UK.
• She authored more than 40 papers in international journals and worked independently for several years in scientific Consultancy as Telethon grant scientific manager, INGM scientific officer at Policlinico Milano, as a medical/scientific writer.
• She has gained extensive scientific experience managing several hundred national grant applications reviewing for International Funding Agencies (UK, India, Singapore), and writing scientific grant proposals (AIRC, CNR, ERC, EIC).
• Reviewer for several international biomedical journals and editor for Frontiers “Experimental Pharmacology and Drug Discovery” since 2020.

Miguel Mutti is a senior executive with 25 years’ experience in general management, business development and M&A, integration and restructuring in the healthcare and pharma industry.
After starting his career in investment banking at Salomon Smith Barney/ Citigroup in the M&A and ECM, Miguel Mutti joined the industry where he spent the last 15 years in various roles and geographies, including General Manager and CEO in US and Italy, Corporate Development Officer at Chemo Group (now Grupo Insud), VP Head of M&A at Grunenthal and SVP Corporate Development Head EMEA and Global Head BD Neurology at Lupin.
Miguel also serves as board advisor to biotech and medtech companies and is currently managing partner at Sin&rgetica Healthcare, an advisory firm advising clients in Corporate and Business Development activities including M&A and licensing, Debt and Equity raising, technical due diligences and commercial assessments, as well as co-investing with clients and partners in selected transactions.

• Since 2010, Paolo is CEO of GDS Communication, a communication and marketing agency in the Healthcare sector, which joined ” The European House Ambrosetti ” in April 2023.

• He is Principal Expert and Member of the Development Committee of “The European House Ambrosetti “.

• Since 2022 he is President of Confindustria Giovani di Como and Vice President of Confindustria Como.

• Since 2023 he is part of the “Rotary Club Como” and “Amici di Como”.

• He graduated in Economics from Università Cattolica del Sacro Cuore and in Marketing from the SGH Warsaw School of Economics.

• He holds certifications in Budgeting and Controlling and in New Digital Communication from the 24h Business School, in Business Accounting from «Chartered Institute of Management Accountants” and in Value-Based medtech: How to Succeed in a Challenging Environment from SDA Bocconi.

• Previously, Paolo has worked for international companies such as Alcon, Carat and Accenture.

• Pierluigi is founder, Chairman and CEO at Genenta, a gene therapy company focused on cancer immunotherapy.

• He has been founder and CEO of Quantica SGR, an Italian Venture Capital firm with 100M€ under management, and Venture consultant for Sofinnova Partners, an European VC leader in Life Sciences with 2.6B€ under management.

• He was investor and Board Member at Ethical Oncology Science, acquired by Clovis Oncology (Nasdaq: CLVS), for up to 420M$ (upfront 200M$ + milestone 220M$), plus 
license with Servier for 80M$.

• Pierluigi raised more than 140M$ from private and institutional Investors and generated 720M$ cash/equity in enterprise value.

• He has been also Independent Member of the Research and Innovation Commission at the Italian Ministry of Health

• Roberto is Vice President Finance at Newron Pharmaceuticals since 2012.

• He joined Newron in 2002. Since, he has covered various managerial positions within the Finance Department and has been involved in the IPO, secondary fund raising, M&A and other strategic corporate transactions.

• He started as auditor at Coopers&Lybrand (CL), before joining PricewaterhouseCoopers (PwC) where he served as Senior Auditor & Business Advisor dealing with companies from the pharmaceutical, fashion, energy and automotive industries.

• He has more than 18 years of experience in biotech, finance and auditing.

• He holds a degree in Business Economics from the University Luigi Bocconi in Milan and he is registered with the national register of auditors.

• Roberto has extensive international accounting, controlling and tax experience overseeing Newron group subsidiaries based in Sweden, Switzerland, USA and UK.